A Study to Evaluate the Efficacy and Safety of LZM012 - Trial NCT06110676
Access comprehensive clinical trial information for NCT06110676 through Pure Global AI's free database. This Phase 3 trial is sponsored by Livzon Pharmaceutical Group Inc. and is currently Recruiting. The study focuses on Psoriasis. Target enrollment is 918 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Livzon Pharmaceutical Group Inc.
Timeline & Enrollment
Phase 3
Aug 21, 2023
Jun 01, 2025
Primary Outcome
PASI100 response rate
Summary
This study is a muti-center, randomized, double blind, positive control phase III clinical
 study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque
 psoriasis patients
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06110676
Non-Device Trial